|
|
|
|
|
Legal status
Patent in force
| (51) | INT.CL. | C07D 401/12 | (2006.01) |
| C07D 231/56 | (2006.01) | ||
| C07D 209/40 | (2006.01) | ||
| C07D 209/42 | (2006.01) | ||
| C07D 209/48 | (2006.01) | ||
| C07D 487/04 | (2006.01) | ||
| C07D 471/04 | (2006.01) | ||
| C07D 403/12 | (2006.01) | ||
| C07D 403/04 | (2006.01) | ||
| C07D 403/06 | (2006.01) | ||
| A61K 31/416 | (2006.01) | ||
| A61K 31/4439 | (2006.01) | ||
| A61K 31/404 | (2006.01) | ||
| A61K 31/4035 | (2006.01) | ||
| A61P 37/00 | (2006.01) | ||
| A61P 37/06 | (2006.01) | ||
| A61P 25/00 | (2006.01) | ||
| A61P 25/28 | (2006.01) | ||
| A61P 13/12 | (2006.01) | ||
| A61P 9/00 | (2006.01) | ||
| A61P 21/04 | (2006.01) | ||
| C07D 401/04 | (2006.01) | ||
| C07D 401/06 | (2006.01) | ||
| C07D 401/14 | (2006.01) | ||
| C07D 405/12 | (2006.01) | ||
| C07D 209/12 | (2006.01) | ||
| A61P 13/00 | (2006.01) |
| (11) | Number of the document | 3411411 |
| (13) | Kind of document | T |
| (96) | European patent application number | 17748044.9 |
| Date of filing the European patent application | 2017-02-01 | |
| (97) | Date of publication of the European application | 2018-12-12 |
| (45) | Date of publication and mention of the grant of the patent | 2021-05-19 |
| (46) | Date of publication of the claims translation | 2021-06-25 |
| (86) | Number | PCT/US2017/015953 |
| Date | 2017-02-01 |
| (87) | Number | WO 2017/136395 |
| Date | 2017-08-10 |
| (30) | Number | Date | Country code |
| 201662289653 P | 2016-02-01 | US |
| (72) |
KOTIAN, Pravin, L., US
BABU, Yarlagadda, S., US
ZHANG, Weihe, US
VOGETI, Lakshminarayana, US
WU, Minwan, US
CHINTAREDDY, Venkat, R., US
RAMAN, Krishnan, US
|
| (73) |
Biocryst Pharmaceuticals, Inc.,
4505 Emperor Blvd., Durham, North Carolina 27703,
US
|
| (74) |
Reda ŽABOLIENĖ,
METIDA, Verslo centras "VERTAS", Gynėjų g. 16, LT-01109 Vilnius,
LT
|
| (54) | 1H-indazol-3-karboksamidų dariniai ir susiję junginiai, kaip D faktoriaus inhibitoriai, skirti gydyti ligas, kurioms būdingas aberantinės komplemento sistemos aktyvumas, tokias kaip imunologiniai sutrikimai |
| 1H-INDAZOLE-3-CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS FACTOR D INHIBITORS FOR TREATING DISEASES CHARACTERIZED BY ABERRANT COMPLEMENT SYSTEM ACTIVITY, SUCH AS E.G. IMMUNOLOGICAL DISORDERS |
| Payment date | Validity (years) | Amount | |
| 2025-12-17 | 10 | 231.00 EUR |
| 2027-02-01 |